Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Sunday movies....thanks for posting
View:
Post by Aprilstocksgoup on Dec 05, 2022 8:49pm

Sunday movies....thanks for posting

but please enlighten us on why this is such a steal at these prices???  We got Fast track status on mBC awhile back...it did zip for the shares...so why will Fast track on Panc be any different.  The panc studies were done on tiny numbers of patients....there is some question about whether the results can be projected on to larger populations. And the results were only good because there is an unmet need here....the actual improvements in the patients were small and incremental.  Yes pela is safe and has some effect...but we are not curing cancer here.    Canada always says the BPs have done a ton of due diligence on our company...but he is way exaggerating the implications of this....these BPs are just allowing us to play around with their drugs in controlled studies.....they do this with hundreds of small bios.  Phase III is still a ways off for both panc and MBc....phase III is typically when the BPs will start taking notice...I understand the BPS may want to run the phase III...and may acquire us...in fact that has to happen because we are running out of cash....of course the company keeps hitting the ATM anytime the stock moves up a few cents and that keeps the stock from running to any decent degree....i am just not seeing any urgency to buy here and the market seems to agree,,,volume and stock appreciation are minimal....sure we have had a small run of late....but most of us are stuck in this issue at much higher prices.....this forum is dominated by pumpers who have been sitting here for decades in many cases....it took a while for the scales to fall from my eyes on this issue
Comment by SundayMovies on Dec 05, 2022 9:40pm
Lots of questions.  Before we get into the fundamentals. Let's play the momentum analysis here. All technical indicators are flashing GREEN. Today's action was quite bullish. The general market was absolutely bearish thinking about rate hikes and an imminent recession, yet this stock did not crash below 1.85 us and ended at 1.93 (even touching 2.00 in after hours) to settle at 1.96 ...more  
Comment by Aprilstocksgoup on Dec 06, 2022 9:38am
Thanks Sunday....my fingers are crossed...but i am just not seeing this thing moving anytime soon......its had so many false starts I don't believe anything anymore.  
Comment by fox7mf on Dec 06, 2022 9:55am
Roche will buyout Onc long before the 6 month mark...my opinion. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities